Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina.
RANOLAZINE
Structure
Product Description
Details |
|
|---|---|
Chemical Name |
RANOLAZINE |
IUPAC Name |
(RS)-N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl]acetamide |
CAS Number |
142387-99-3 |
Molecular Formula |
C24H33N3O4 |
Synonyms |
RANOLAZINE;n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethy]piperazine;CVT 303;Ranexa;Renexa;RS 43285-003;1-Piperazineacetamide,N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]- |
Application |
For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates. |